My watch list
my.bionity.com  
Login  

07-10-2010: Bavarian Nordic A/S announced that the company successfully defended its core patent covering the MVA-BN® technology despite aggressive attempts from competitors to revoke the patent in Europe.

The patent was granted in December 2005 and after the nine month opposition period in which any third party can file an opposition against any patent granted in a European jurisdiction, seven companies opposed the patent. The opposition proceeding has been pending at the European Patent Office for several years.

After an oral hearing in the first instance the Opposition Division today rendered its decision to uphold the patent with certain amended claims.

Bavarian Nordic's President & CEO, Anders Hedegaard commented: "We are very pleased with the decision by the first instance to uphold our core patent, thus confirming its uniqueness. We have substantially invested our resources to develop our MVA BN® technology and our efforts have led to the creation of valuable intellectual property, which we successfully have defended today."

Watchlist

This is where you can add this news to your personal favourites

Facts, background information, dossiers
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE